NAS:XDNA
Kelly CRISPR & Gene Editing Technology ETF | |
$ 7.38 0 ( +0%) 11:51 AM EST | |
PE Ratio:
25.51
PB Ratio:
2.4
Volume:
-
Dividend Yield %:
0
| |
Last Holding update 2024-01-24 | 23 Stocks (0 new) |
Value $3.00 Mil | Turnover 17 % |
Portfolio Report | |
Registrant: Kelly CRISPR & Gene Editing Technology ETF
|
Kelly CRISPR & Gene Editing Technology ETF Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Kelly CRISPR & Gene Editing Technology ETF Key Statistics
Name | Value | ||
---|---|---|---|
Day's Open ($) | 7.38 | ||
Day's Range ($) | 7.38 - 7.38 | ||
Day's Volume | |||
52-Week Range ($) | 5.87 - 9.38 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility | - | ||
14-Day RSI | - | ||
14-Day ATR ($) | 0.072143 | ||
20-Day SMA ($) | - |
Fundamental Data
Name | Value | ||
---|---|---|---|
Market Cap (Mil $) | 2.583 | ||
Shares Outstanding (Mil) | - | ||
PE Ratio | 25.51 | ||
PE Ratio (10y Range) | 18.6 - 25.51 | ||
PE Ratio (10y Median) | 25.51 | ||
PB Ratio | 2.4 | ||
PB Ratio (10y Range) | 2.21 - 3.08 | ||
PB Ratio (10y Median) | 2.4 |
Dividend Data
Name | Value | ||
---|---|---|---|
Dividends per Share (TTM) ($) | - | ||
Dividend Yield % | - | ||
Dividend Yield % (10y Range) | 0.08 - 0.16 | ||
Dividend Yield % (10y Median) | 0.1 | ||
Next Dividend Payment Date | |||
Dividend Frequency | - |
XDNA Kelly CRISPR & Gene Editing Technology ETF Fundamental Charts
Historical TTM Price-to-Earnings for XDNA Kelly CRISPR & Gene Editing Technology ETF
Historical TTM Price-to-Earnings without NRI for XDNA Kelly CRISPR & Gene Editing Technology ETF
Historical Price-to-Book Ratio for XDNA Kelly CRISPR & Gene Editing Technology ETF
Historical Dividend Yields for XDNA Kelly CRISPR & Gene Editing Technology ETF
Kelly CRISPR & Gene Editing Technology ETF Technical Indicators
Moving Average
Momentum
Gurus Latest Trades with NAS:XDNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:XDNA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Kelly CRISPR & Gene Editing Te... Top Holdings of 2023-11-30
View Full List
Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
---|---|---|---|---|---|---|---|---|---|---|---|---|
CRSP | CRISPR Therapeutics AG | 5,698 | 380.2 | +35.28% | 14.760 | +3.85% | 0.010 | -3.35% | +6.35% | 3,615.2 | Biotechnology | |
BEAM | Beam Therapeutics Inc | 12,306 | 345.6 | +45.87% | 13.410 | +4.22% | 0.020 | -31.83% | -25.10% | 1,867.8 | Biotechnology | |
TMO | Thermo Fisher Scientific Inc | 518 | 256.8 | -1.89% | 9.970 | -0.23% | 0.000 | -23.77% | -22.68% | 151,714.8 | Medical Diagnostics & Research | |
NTLA | Intellia Therapeutics Inc | 7,616 | 225.7 | +5.43% | 8.760 | +0.45% | 0.010 | -18.28% | -30.62% | 838.0 | Biotechnology | |
PRME | Prime Medicine Inc | 21,546 | 156.4 | +144.29% | 6.070 | +3.59% | 0.020 | -26.52% | -42.12% | 221.9 | Biotechnology | |
EDIT | Editas Medicine Inc | 14,406 | 151.7 | +9.24% | 5.890 | +0.50% | 0.020 | +7.30% | +50.39% | 159.9 | Biotechnology | |
CRBU | Caribou Biosciences Inc | 21,784 | 127.9 | -20.62% | 4.960 | -1.37% | 0.020 | +8.62% | -20.75% | 117.2 | Biotechnology | |
VERV | Verve Therapeutics Inc | 9,968 | 112.4 | +27.40% | 4.360 | +0.94% | 0.010 | -6.28% | +9.84% | 552.2 | Biotechnology | |
PSTX | Poseida Therapeutics Inc | 41,412 | 110.6 | -22.38% | 4.290 | -1.02% | 0.040 | +269.65% | -1.04% | 925.9 | Biotechnology | |
ABBV | AbbVie Inc | 728 | 103.7 | -9.45% | 4.020 | -0.46% | 0.000 | -9.09% | +8.83% | 335,316.3 | Drug Manufacturers |
Kelly CRISPR & Gene Editing Technology ETF's Historical Top Holdings Breakdowns
Kelly CRISPR & Gene Editing Technology ETF's Top Stock Picks
View Full List
Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
---|---|---|---|---|---|---|---|---|---|---|---|
BEAM | Beam Therapeutics Inc | 2023-11-30 | Add | +4.22% | 17.69 ($23.62) 30.76 | $18.57 | -21.36% | Add 45.87% | 12,306 | 3,870 | |
CRSP | CRISPR Therapeutics AG | 2023-11-30 | Add | +3.85% | 38.62 ($49.87) 72.18 | $41.86 | -16.06% | Add 35.28% | 5,698 | 1,486 | |
PRME | Prime Medicine Inc | 2023-11-30 | Add | +3.59% | 5.59 ($8.68) 13.24 | $1.69 | -80.53% | Add 144.29% | 21,546 | 12,726 | |
DTIL | Precision BioSciences Inc | 2023-11-30 | Reduce | -1.57% | 8.58 ($11.01) 14.1 | $5.49 | -50.14% | Reduce -56.92% | 2,087 | -82,812 | |
XPAR:SAN | Sanofi SA | 2023-11-30 | Add | +1.47% | 81.44 (€95.27) 103.98 | €88.41 | -7.20% | Add 80.56% | 910 | 406 | |
CRBU | Caribou Biosciences Inc | 2023-11-30 | Reduce | -1.37% | 3.58 ($4.82) 6.39 | $1.26 | -73.86% | Reduce -20.62% | 21,784 | -5,660 | |
TSVT | 2seventy bio Inc | 2023-11-30 | Add | +1.04% | 1.57 ($3.3) 5.19 | $5.00 | 51.52% | Add 143.54% | 24,724 | 14,572 | |
PSTX | Poseida Therapeutics Inc | 2023-11-30 | Reduce | -1.02% | 1.83 ($2.26) 2.85 | $9.50 | 320.35% | Reduce -22.38% | 41,412 | -11,940 | |
VERV | Verve Therapeutics Inc | 2023-11-30 | Add | +0.94% | 8.84 ($12.21) 18.7 | $6.20 | -49.26% | Add 27.4% | 9,968 | 2,144 | |
ALLO | Allogene Therapeutics Inc | 2023-11-30 | Add | +0.91% | 2.28 ($3.18) 4.19 | $1.42 | -55.35% | Add 43.07% | 32,998 | 9,934 |
Kelly CRISPR & Gene Editing Technology ETF Total Holding History ($B)
Kelly CRISPR & Gene Editing Technology ETF's Asset Allocation
Kelly CRISPR & Gene Editing Technology ETF Past Portfolios
Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
---|---|---|---|---|
Top Ranked Articles
- 1
Kelly CRISPR & Gene Editing Technology ETF's Hypothetical Growth since 2023-11-30
Kelly CRISPR & Gene Editing Technology ETF's Yearly Returns
Year | Portfolio % | % | Excess Gain % |
---|
Kelly CRISPR & Gene Editing Technology ETF's Holdings Heat Map
Size field:
Kelly CRISPR & Gene Editing Technology ETF's Holdings Bubble Chart
Kelly CRISPR & Gene Editing Technology ETF News
- 1
Discussions on Kelly CRISPR & Gene Editing Technology ETF
No discussions yet.